Certolizumab pegol for moderate to severe Crohn's disease - horizon scanning review
NHSC
Record ID 32004000891
English
Authors' objectives:
This study aims to summarise the currently available evidence on certolizumab pegol for moderate to severe Crohn's disease.
Authors' recommendations:
Certolizumab pegol (CDP-870, PHA-738144) is a PEGylated, Fab' fragment of a humanised anti-TNFa monoclonal antibody that is administered by subcutaneous injection initially every 2 weeks then every 4 weeks for maintenance. It is in phase III trials for the treatment of moderate to severe Crohn's disease. Two phase II, placebo-controlled, randomised trials have been published in abstract form showing a trend towards increased improvement or remission of symptoms with certolizumab pegol. Certolizumab pegol is also in development for rheumatoid arthritis.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Crohn Disease
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.